Skip to main content
. 2020 Dec 23;8(12):e3316. doi: 10.1097/GOX.0000000000003316

Fig. 4.

Fig. 4.

Photographs of a 2-level composite responder to CCH treatment (ie, 2-level improvement from RCT baseline at day 71 in both CR-PCSS and PR-PCSS) in the buttock (A) and thigh (B), with durability of response through Day 720. Reprinted with permission from Endo Pharmaceuticals Inc. © 2020 All rights reserved.